Generic Semaglutide Set to Expand Access

Semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, was first approved by the FDA in 2017 for treating type 2 diabetes. Its subsequent approval for weight management has fueled a surge in demand, addressing a significant public health issue with over 40% of American adults affected by obesity. The high cost of brand-name semaglutide, with list prices often exceeding $1,000 per month, has created a significant barrier to access for many patients. In response to public and political pressure, manufacturer Novo Nordisk has announced price reductions of up to 50% for some of its semaglutide products, which are expected to take effect in January 2027. The path to a generic version in the United States is complex due to a web of patents held by Novo Nordisk. While some foundational patents are expiring, others related to the drug's formulation and delivery device extend market exclusivity until at least 2031-2032. This has not stopped generic drug manufacturers from preparing for market entry. Several pharmaceutical companies, including Mylan (a part of Viatris) and Sun Pharmaceutical, have already filed Abbreviated New Drug Applications (ANDAs) with the FDA for generic versions of Wegovy. These filings have triggered patent infringement lawsuits from Novo Nordisk, a standard procedure in the pharmaceutical industry that can precede a potential market entry. While U.S. patients may have to wait, generic semaglutide is expected to be available sooner in other parts of the world. Patents in countries like China and India are set to expire around 2026, and numerous companies in those regions are gearing up for production. In the interim, the FDA has warned consumers about the risks of using unapproved, "compounded" versions of semaglutide. Novo Nordisk has also taken legal action against numerous compounding pharmacies and telehealth companies to halt the sale of these unauthorized products.